-
1
-
-
84975856269
-
Economic costs of diabetes in the U.S
-
American Diabetes Association. Economic costs of diabetes in the U.S. in 2012 Diabetes Care. 2013;36(4):1033-46.
-
(2013)
in 2012 Diabetes Care
, vol.36
, Issue.4
, pp. 1033-1046
-
-
-
2
-
-
84855690825
-
Effective interventions for stemming the growing crisis of diabetes and prediabetes: a national payer's perspective
-
Vojta D, De Sa J, Prospect T, Stevens S. Effective interventions for stemming the growing crisis of diabetes and prediabetes: a national payer's perspective. Health Aff(Millwood). 2012;31(1):20-26.
-
(2012)
Health Aff(Millwood)
, vol.31
, Issue.1
, pp. 20-26
-
-
Vojta, D.1
De Sa, J.2
Prospect, T.3
Stevens, S.4
-
3
-
-
84960878943
-
2016 standards of medical care in diabetes
-
American Diabetes Association. 2016 standards of medical care in diabetes. Diabetes Care. 2016;39(Supplement 1):S1-2.
-
(2016)
Diabetes Care
, vol.39
, pp. S1-S2
-
-
-
4
-
-
84856075028
-
-
Comprehensive diabetes care. October 1. Accessed January 25, 2017
-
National Committee for Quality Assurance. HEDIS 2009 Volume 2 technical update. Comprehensive diabetes care. October 1, 2008. Available at: http://www.ncqa.org/portals/0/PolicyUpdates/HEDIS%20Technical%20 Updates/09_CDC_Spec.pdf. Accessed January 25, 2017.
-
(2008)
HEDIS 2009 Volume 2 technical update
-
-
-
6
-
-
85021361996
-
-
Accessed January 16, 2017
-
Centers for Medicare & Medicaid Services. Quality payment program. 2016 Available at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/Value-Based-Programs/MACRA-MIPSand-APMs/Quality-Payment-Program-MACRA-NPRM-Slides.pdf. Accessed January 16, 2017.
-
(2016)
Quality payment program
-
-
-
7
-
-
84982995031
-
AACE/ACE comprehensive diabetes management algorithm, 2015
-
Garber AJ, Abrahamson MJ, Barzilay Jl, et al. AACE/ACE comprehensive diabetes management algorithm, 2015. Endocr Pract. 2015;21(4):438-47.
-
(2015)
Endocr Pract
, vol.21
, Issue.4
, pp. 438-447
-
-
Garber, A.J.1
Abrahamson, M.J.2
Barzilay, J.3
-
8
-
-
84872084453
-
Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
-
Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013;381(9861):117-24.
-
(2013)
Lancet
, vol.381
, Issue.9861
, pp. 117-124
-
-
Buse, J.B.1
Nauck, M.2
Forst, T.3
-
9
-
-
84924289309
-
Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes
-
Blonde L, Pencek R, MacConell L. Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes. Cardiovasc Diabetol. 2015;14:12.
-
(2015)
Cardiovasc Diabetol
, vol.14
, pp. 12
-
-
Blonde, L.1
Pencek, R.2
MacConell, L.3
-
10
-
-
84922790807
-
GLP-1 receptor agonists: a review of head-to-head clinical studies
-
Trujillo JM, Nuffer W, Ellis SL. GLP-1 receptor agonists: a review of head-to-head clinical studies. Ther Adv Endocrinol Metab. 2015;6(1):19-28.
-
(2015)
Ther Adv Endocrinol Metab
, vol.6
, Issue.1
, pp. 19-28
-
-
Trujillo, J.M.1
Nuffer, W.2
Ellis, S.L.3
-
12
-
-
55249084180
-
The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients
-
Charlson ME, Charlson RE, Peterson JC, Marinopoulos SS, Briggs WM, Hollenberg JP. The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. J Clin Epidemiol. 2008;61(12):1234-40.
-
(2008)
J Clin Epidemiol
, vol.61
, Issue.12
, pp. 1234-1240
-
-
Charlson, M.E.1
Charlson, R.E.2
Peterson, J.C.3
Marinopoulos, S.S.4
Briggs, W.M.5
Hollenberg, J.P.6
-
13
-
-
84942578393
-
Why summary comorbidity measures such as the Charlson Comorbidity Index and Elixhauser Score work
-
Austin SR, Wong YN, Uzzo RG, Beck JR, Egleston BL. Why summary comorbidity measures such as the Charlson Comorbidity Index and Elixhauser Score work. Med Care. 2015;53(9):e65-72.
-
(2015)
Med Care
, vol.53
, Issue.9
, pp. e65-e72
-
-
Austin, S.R.1
Wong, Y.N.2
Uzzo, R.G.3
Beck, J.R.4
Egleston, B.L.5
-
14
-
-
84920855422
-
Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis
-
Sun F, Wu S, Wang J, et al. Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis. Clin Ther. 2015;37(1):225-41.
-
(2015)
Clin Ther
, vol.37
, Issue.1
, pp. 225-241
-
-
Sun, F.1
Wu, S.2
Wang, J.3
-
15
-
-
84879800350
-
Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials
-
Wang B, Zhong J, Lin H, et al. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. Diabetes Obes Metab. 2013;15(8):737-49.
-
(2013)
Diabetes Obes Metab
, vol.15
, Issue.8
, pp. 737-749
-
-
Wang, B.1
Zhong, J.2
Lin, H.3
-
16
-
-
84860638209
-
The cardiovascular effects of GLP-1 receptor agonists
-
Okerson T, Chilton RJ. The cardiovascular effects of GLP-1 receptor agonists. Cardiovasc Ther. 2012;30(3):e146-55.
-
(2012)
Cardiovasc Ther
, vol.30
, Issue.3
, pp. e146-e155
-
-
Okerson, T.1
Chilton, R.J.2
|